Duration of Postvaccination Neutralizing Antibodies to SARS-CoV-2 and Medication Effects: Results from the Safety and Immunogenicity of COVID-19 Vaccination in Systemic Immune-Mediated Inflammatory Diseases Cohort Study

被引:0
|
作者
Habib, Rami [1 ]
Dayam, Roya M. [2 ]
Hitchon, Carol [3 ]
Chandran, Vinod [4 ,5 ]
Fortin, Paul R. [6 ]
Boire, Gilles [7 ]
Bowdish, Dawn M. E. [8 ]
Gingras, Anne-Claude [2 ]
Flamand, Louis [6 ,9 ]
Larche, Maggie J. [8 ]
Colmegna, Ines [1 ]
Lukusa, Luck [1 ]
Lee, Jennifer L. F. [1 ]
Pereira, Daniel [10 ]
Bernstein, Charles N. [3 ]
Lalonde, Nadine [11 ]
Turnbull, Elizabeth [1 ]
Bernatsky, Sasha [1 ]
机构
[1] McGill Univ, Montreal, PQ, Canada
[2] Mt Sinai Hosp, Sinai Hlth, Toronto, ON, Canada
[3] Univ Manitoba, Winnipeg, MB, Canada
[4] Univ Hlth Network, Schroeder Arthrit Inst, Krembil Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Univ Laval, Ctr Hosp Univ CHU Quebec, Res Ctr, Quebec City, PQ, Canada
[7] Univ Sherbrooke, Sherbrooke, PQ, Canada
[8] McMaster Univ, Hamilton, ON, Canada
[9] Univ Laval, Quebec City, PQ, Canada
[10] Univ Hlth Network, Schroeder Arthrit Inst, Krembil Res Inst, Toronto, ON, Canada
[11] Canadian Arthrit Patient Alliance, Toronto, ON, Canada
关键词
D O I
10.1002/acr2.11697
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveIn the face of the ongoing circulation of SARS-CoV-2, the durability of neutralization post-COVID-19 vaccination in immune-mediated inflammatory disease (IMID) is a key issue, as are the effects of medications.MethodsAdults (n = 112) with inflammatory bowel disease, psoriasis/psoriatic arthritis, rheumatoid arthritis, spondylarthritis, and systemic lupus were recruited from participating Canadian medical centers from 2021 to 2023. We focused on log-transformed neutralization (lentivirus methods) as a continuous outcome, with separate models for wild-type and Omicron strains BA.1 and BA.5.ResultsCompared with 30 to 120 days postvaccination, subsequent periods were associated with greater neutralization in unadjusted models for wild-type, BA.1, and BA.5 strains and against the BA.1 strain in adjusted models. Rituximab was associated with lower neutralization for the BA.1 strain in adjusted models, with a similar trend for BA.5. In methotrexate users, there were trends for less neutralization of BA.1 and BA.5 in all unadjusted models, whereas in adjusted models, there was significantly lower neutralization only for the wild type. Three or more doses and Omicron-specific vaccines were both independently associated with better neutralization ability for all three strains. A COVID-19 infection within six months before sampling was associated with higher neutralization of wild type and BA.1 in adjusted analyses. Anti-tumor necrosis factor agents were associated with lower neutralization ability for BA.5 in adjusted analyses.ConclusionNeutralization responses in immunosuppressed individuals with IMID were durable over time and were augmented by more than three doses and Omicron-specific vaccines. Less neutralization was seen with certain medications. Our work clarifies the joint effects of vaccine history, infection, and medications on COVID-19 immunity.
引用
下载
收藏
页数:6
相关论文
共 50 条
  • [1] IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
    Reddy, Kavya
    Grody, Wayne W.
    Sarkissian, Ariella
    Getzug, Terri
    GASTROENTEROLOGY, 2022, 162 (07) : S287 - S287
  • [2] Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study
    Jorgensen, K. K.
    Syversen, S. W.
    Jyssum, I.
    Tveter, A. T.
    Tran, T. T.
    Sexton, J.
    Provan, S. A.
    Mjaaland, S.
    Warren, D. J.
    Kvien, T. K.
    Grodeland, G.
    Nissen-Meyer, L. S.
    Ricanek, P.
    Chopra, A.
    Andersson, A. M.
    Kro, G. B.
    Jahnsen, J.
    Munthe, L. A.
    Haavardsholm, E. A.
    Vaage, J. T.
    Lund-Johansen, F.
    Goll, G. L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I537 - I538
  • [3] Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study
    Jorgensen, K. K.
    Syversen, S. W.
    Jyssum, I.
    Tveter, A. T.
    Tran, T. T.
    Sexton, J.
    Provan, S. A.
    Mjaaland, S.
    Warren, D. J.
    Kvien, T. K.
    Grodeland, G.
    Nissen-Meyer, L. S.
    Ricanek, P.
    Chopra, A.
    Andersson, A. M.
    Kro, G. B.
    Jahnsen, J.
    Munthe, L. A.
    Haavardsholm, E. A.
    Vaage, J. T.
    Lund-Johansen, F.
    Goll, G. L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I537 - I538
  • [4] Immunogenicity After Primary COVID-19 Vaccination in Patients with Immune-mediated Inflammatory Diseases: A Comparative Cohort Study
    Kastrati, Kastriot
    Mrak, Daniel
    Weber, Peter
    Goethans, Lena
    Hana, Claudia
    Simader, Elisabeth
    Hummel, Thomas
    Friedberg, Eleonora
    Aletaha, Daniel
    Bonelli, Michael
    Radner, Helga
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2383 - 2385
  • [5] The Immunogenicity and Safety of Three Types of SARS-CoV-2 Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Longitudinal Cohort Study
    Tien, Ni
    Chang, Yu-Chang
    Chen, Po-Ku
    Lin, Hui-Ju
    Chang, Shih-Hsin
    Lan, Joung-Liang
    Hsueh, Po-Ren
    Chang, Ching-Kun
    Chen, Der-Yuan
    BIOMEDICINES, 2022, 10 (04)
  • [6] Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
    Syversen, Silje Watterdal
    Jyssum, Ingrid
    Tveter, Anne Therese
    Sexton, Joe
    Christensen, Ingrid Egeland
    Tran, Trung T.
    Bjorlykke, Kristin Hammersboen
    Mjaaland, Siri
    Warren, David J.
    Kvien, Tore K.
    Chopra, Adity
    Kro, Grete Birkeland
    Jahnsen, Jorgen
    Munthe, Ludvig A.
    Haavardsholm, Espen A.
    Grodeland, Gunnveig
    Vaage, John Torgils
    Provan, Sella Aarrestad
    Jorgensen, Kristin Kaasen
    Goll, Guro Lovik
    RMD OPEN, 2022, 8 (02):
  • [7] Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
    Jyssum, Ingrid
    Tveter, Anne Therese
    Sexton, Joe
    Christensen, Ingrid Egeland
    Mjaaland, Siri
    Warren, David
    Kvien, Tore K.
    Bjorlykke, Kristin Hammersboen
    Kro, Grete Birkeland
    Jahnsen, Jorgen
    Munthe, Ludvig A.
    Haavardsholm, Espen
    Grodeland, Gunnveig
    Provan, Sella Aarrestad
    Jorgensen, Kristin Kaasen
    Goll, Guro
    Syversen, Silje Watterdal
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1575 - 1577
  • [8] Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
    Kartnig, Felix
    Mrak, Daniel
    Simader, Elisabeth
    Tobudic, Selma
    Radner, Helga
    Mandl, Peter
    Goeschl, Lisa
    Hommer, Nikolaus
    Mayer, Margareta
    Hofer, Philipp
    Hummel, Thomas
    Deimel, Thomas
    Gessl, Irina
    Puchner, Antonia
    Kerschbaumer, Andreas
    Thalhammer, Renate
    Handisurya, Alessandra
    Kain, Renate
    Winkler, Stefan
    Smolen, Josef S.
    Stiasny, Karin
    Perkmann, Thomas
    Haslacher, Helmuth
    Aberle, Judith H.
    Aletaha, Daniel
    Heinz, Leonhard X.
    Sieghart, Daniela
    Bonelli, Michael
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (02) : 292 - 300
  • [9] Safety and Immunogenicity of COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED): Preliminary Results on Severe Adverse Events
    Tsyruk, Olga
    Kaplan, Gilaad
    Fortin, Paul
    Hitchon, Carol
    Chandran, Vinod
    Larche, Maggie
    Avina-Zubieta, Antonio
    Boire, Gilles
    Colmegna, Ines
    Lacaille, Diane
    Lalonde, Nadine
    Proulx, Laurie
    Gunderson, Janet
    Richards, Dawn
    Allard-Chamard, Hugues
    Roux, Sophie
    Kirmani, Ayesha
    Lodhi, Sumiya
    Heesels, Lauren
    Markovinovic, Ante
    Lukusa, Luck
    Pereira, Daniel
    Lee, Jennifer
    Bernatsky, Sasha
    JOURNAL OF RHEUMATOLOGY, 2024, 51 : 38 - 38
  • [10] Safety & ImmUnogenicity of COVID-19 VaCcines in SystEmic immunE Mediated Inflammatory Diseases (SUCCEED)
    Tsyruk, Olga
    Chandran, Vinod
    Hitchon, Carol
    Avina-Zubieta, J. Antonio
    Colmegna, Ines
    Fortin, Paul R.
    Larche, Maggie
    Boire, Gilles
    Lukusa, Luck
    Bowish, Dawn
    Kaplan, Gilaad G.
    Pereira, Daniel
    Dayam, Roaya
    Lee, Jennifer L. F.
    Turnbull, Elizabeth
    Valerio, Valeria
    Proulx, Laurie
    Gunderson, Janet
    Gingras, Anne-Claude
    Bernatsky, Sasha
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3565 - 3568